Company intelligence / Profile preview

OAE

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

OAE Biotherapeutics is an early-stage biotechnology company focused on developing novel therapeutic antibodies for complex diseases. The company's name reflects its primary therapeutic pillars: Oncology, Autoimmunity, and Endocrinology. Leveraging a proprietary antibody engineering platform, OAE aims to create highly specific and potent biologics that address unmet medical needs in these three core areas. While currently operating in a relatively stealth-like mode, the company is building a pipeline of next-generation antibody candidates designed to modulate critical disease pathways.

Therapeutic areas: OncologyEndocrinologyImmunology
Modalities: Monoclonal antibodyAntibodyProtein
Industry: Biotech

Beyond the preview

Go deeper on OAE.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OAE.

Explore the full profile